Keros Therapeutics, Inc. (KROS)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 90M 180M 270M Q4 '19: 10M Q1 '20: 7.5M Q2 '20: 5M Q3 '20: 2.5M Q4 '20: 0 Q1 '21: 0 Q2 '21: 100K Q3 '21: 100K Q4 '21: 20.1M Q1 '22: 20.1M Q2 '22: 20M Q3 '22: 20M Q4 '22: 0 Q1 '23: 0 Q2 '23: 0 Q3 '23: 8K Q4 '23: 151K Q1 '24: 234K Q2 '24: 271K Q3 '24: 651K Q4 '24: 3.5M Q1 '25: 214.7M Q2 '25: 232.8M Q3 '25: 246.7M Q4 '25: 244.1M Q1 '26: 33.2M Q2 '26: 15M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-240M -160M -80M 0 80M 160M 240M Q4 '19: -10.6M Q1 '20: -18.2M Q2 '20: -26.5M Q3 '20: -36.1M Q4 '20: -46.7M Q1 '21: -51.9M Q2 '21: -56.5M Q3 '21: -64.8M Q4 '21: -56.4M Q1 '22: -64.7M Q2 '22: -79.9M Q3 '22: -87.7M Q4 '22: -114.8M Q1 '23: -129.5M Q2 '23: -140.1M Q3 '23: -155.4M Q4 '23: -169.9M Q1 '24: -179.6M Q2 '24: -188.7M Q3 '24: -204M Q4 '24: -210.8M Q1 '25: -10.3M Q2 '25: 312K Q3 '25: 43.6M Q4 '25: 67.6M Q1 '26: -110.3M Q2 '26: -101.5M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Net Income TTM

-210M -140M -70M 0 70M 140M 210M Q4 '19: -12.3M Q1 '20: -21M Q2 '20: -28.9M Q3 '20: -37.4M Q4 '20: -45.4M Q1 '21: -49.4M Q2 '21: -54.2M Q3 '21: -62.5M Q4 '21: -58.7M Q1 '22: -67M Q2 '22: -78.7M Q3 '22: -81.9M Q4 '22: -104.7M Q1 '23: -116.3M Q2 '23: -126.5M Q3 '23: -142.5M Q4 '23: -153M Q1 '24: -160.3M Q2 '24: -168.1M Q3 '24: -181.6M Q4 '24: -187.4M Q1 '25: 4.2M Q2 '25: 18.8M Q3 '25: 64.4M Q4 '25: 87M Q1 '26: -85.1M Q2 '26: -83.2M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-180M -120M -60M 0 60M 120M 180M Q4 '19: -16M Q1 '20: -21.6M Q2 '20: -26.5M Q3 '20: -34.4M Q4 '20: -36.9M Q1 '21: -39.3M Q2 '21: -47M Q3 '21: -50.6M Q4 '21: -62.1M Q1 '22: -53.1M Q2 '22: -58M Q3 '22: -68.2M Q4 '22: -70.1M Q1 '23: -102.9M Q2 '23: -111.1M Q3 '23: -120.5M Q4 '23: -124.5M Q1 '24: -134.8M Q2 '24: -143.8M Q3 '24: -140.3M Q4 '24: -160.9M Q1 '25: 44.9M Q2 '25: 55M Q3 '25: 88.8M Q4 '25: 107.5M Q1 '26: -57.2M Q2 '26: -48M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Free Cash Flow TTM

-180M -120M -60M 0 60M 120M 180M Q4 '19: -16.3M Q1 '20: -22.1M Q2 '20: -26.8M Q3 '20: -34.7M Q4 '20: -37.2M Q1 '21: -39.6M Q2 '21: -47.8M Q3 '21: -51.5M Q4 '21: -63.2M Q1 '22: -54M Q2 '22: -59M Q3 '22: -69.2M Q4 '22: -71.3M Q1 '23: -105M Q2 '23: -113M Q3 '23: -122.8M Q4 '23: -127M Q1 '24: -137.2M Q2 '24: -146.1M Q3 '24: -142.5M Q4 '24: -162.8M Q1 '25: 43.3M Q2 '25: 53.1M Q3 '25: 87.1M Q4 '25: 106M Q1 '26: -58.3M Q2 '26: -48.5M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 15M 30M 45M Q2 '20: 17.6M Q3 '20: 20.2M Q1 '21: 23.2M Q2 '21: 23.3M Q3 '21: 23.4M Q1 '22: 24M Q2 '22: 24.1M Q3 '22: 25.5M Q1 '23: 28.4M Q2 '23: 29.6M Q3 '23: 29.7M Q1 '24: 35.7M Q2 '24: 36.1M Q3 '24: 37.6M Q1 '25: 41M Q2 '25: 40.6M Q3 '25: 40.6M Q1 '26: 19.6M Q2 '26: 19.8M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-10.50 -7.00 -3.50 0.00 3.50 7.00 10.50 Q4 '19: -6.08 Q1 '20: -9.58 Q2 '20: -8.76 Q3 '20: -7.65 Q4 '20: -6.61 Q1 '21: -2.18 Q2 '21: -2.23 Q3 '21: -2.50 Q4 '21: -2.52 Q1 '22: -2.85 Q2 '22: -3.31 Q3 '22: -3.36 Q4 '22: -4.16 Q1 '23: -4.41 Q2 '23: -4.55 Q3 '23: -4.96 Q4 '23: -5.20 Q1 '24: -5.15 Q2 '24: -5.13 Q3 '24: -5.21 Q4 '24: -4.99 Q1 '25: -0.16 Q2 '25: 0.33 Q3 '25: 1.56 Q4 '25: 2.30 Q1 '26: -2.53 Q2 '26: -3.22 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.